Compare PROF & CVRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PROF | CVRX |
|---|---|---|
| Founded | N/A | 2000 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 230.4M | 201.0M |
| IPO Year | N/A | 2021 |
| Metric | PROF | CVRX |
|---|---|---|
| Price | $8.24 | $5.19 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 6 |
| Target Price | $12.00 | ★ $13.17 |
| AVG Volume (30 Days) | ★ 288.0K | 257.5K |
| Earning Date | 03-05-2026 | 02-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $14,297,000.00 | ★ $55,969,000.00 |
| Revenue This Year | $64.23 | $11.91 |
| Revenue Next Year | $113.06 | $15.28 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 67.94 | 18.44 |
| 52 Week Low | $3.76 | $4.30 |
| 52 Week High | $8.95 | $18.55 |
| Indicator | PROF | CVRX |
|---|---|---|
| Relative Strength Index (RSI) | 57.22 | 23.14 |
| Support Level | $7.45 | $5.34 |
| Resistance Level | $8.95 | $6.09 |
| Average True Range (ATR) | 0.58 | 0.65 |
| MACD | -0.02 | -0.21 |
| Stochastic Oscillator | 61.13 | 1.43 |
Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of customizable, incision-free therapeutic systems for the image-guided ablation of diseased tissue utilizing its platform technologies and leveraging the healthcare system's existing imaging infrastructure. The company's product TULSA-PRO system combines real-time MRI, robotically driven transurethral sweeping-action thermal ultrasound with closed-loop temperature feedback control for the ablation of prostate tissue. The product is comprised of one-time-use devices and durable equipment that are used in conjunction with a customer's existing MRI scanner.
CVRx Inc is a commercial-stage medical device company focused on developing, manufacturing, and commercializing minimally invasive neuromodulation solutions for patients with cardiovascular diseases. Its proprietary platform technology, Barostim, is designed to leverage the power of the brain to address the imbalance of the Autonomic Nervous System, which causes heart failure and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy which in turn triggers an autonomic response to the heart. The majority of revenue is derived from the USA market.